NASDAQ: NPCE - NeuroPace, Inc.

Rentabilité sur six mois: -54.22%
Secteur: Healthcare

Calendrier des promotions NeuroPace, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.

Plus de détails
The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Цена ао 13.33
Выручка 0.037
EBITDA -0.0201
P/S 5.46
P/BV 3.35
EV/EBITDA -2.92
ISIN US6412881053
Сайт https://www.neuropace.com
Число акций ао 0.02585 млрд
Валюта usd
IPO date 2021-04-22
Sector Health Care
Industry Health Care Equipment & Supplies
Валюта отчета usd
Changement de prix par jour: -0.9288% (6.46)
Changement de prix par semaine: +4.75% (6.11)
Changement de prix par mois: -13.86% (7.43)
Changement de prix sur 3 mois: -12.33% (7.3)
Changement de prix sur six mois: -54.22% (13.98)
Changement de prix par an: +4.07% (6.15)
Evolution du prix sur 3 ans: -61.26% (16.52)
Evolution des prix depuis le début de l'année: -26.35% (8.69)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 3.91 4
P/BV 12.39 1
P/E 0 0
EV/EBITDA -12.13 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % -30.61 0
ROE, % -159.56 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -2.29 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 76.81 8
Rentabilité Ebitda, % 27.21 4
Rentabilité EPS, % -65.26 0
Total: 2.4
Plus de détails

Établissements Volume Partager, %
KCK Limited 5621111 21.39
Orbimed Advisors LLC. 4003967 15.23
Morgan Stanley 2460716 9.36
Soleus Capital Management, L.P. 2433168 9.26
Nantahala Capital Management, LLC 2347354 8.93
Kent Lake Capital, LLC 670946 2.55
FMR, LLC 468081 1.78
Vanguard Group Inc 413106 1.57
Millennium Management LLC 172403 0.66
Geode Capital Management, LLC 115996 0.44

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
ProShares Hedge Replication ETF 0.00058 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.02573 34.327031588619 1.54048
iShares Russell 2000 Growth ETF 0.00726 38.042556988 0.6026
ProShares UltraPro Russell2000 0.0022 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 37.361289927043 0.60264
Vanguard Russell 2000 ETF 0 32.773459189339 1.48801



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Martha J. Morrell Chief Medical Officer 728.68k 1957 (67 années)
Mr. Joel D. Becker CEO, President & Director 762k 1968 (56 années)
Ms. Rebecca L. Kuhn CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary 614.91k 1961 (63 année)
Ms. Kelley Nicholas Vice President of Sales N/A
Ms. Leah Akin Acting General Counsel N/A
Mr. Dylan St. John Chief of Operations & Development

Adresse: United States, Mountain View. CA, 455 North Bernardo Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.neuropace.com